The presence of IFL3/4 rs12979860 C allele influences the in vitro IP-10 production by mononuclear cells from patients with systemic lupus erythematosus
Restricted accessReview articleFirst published online April, 2020
The presence of IFL3/4 rs12979860 C allele influences the in vitro IP-10 production by mononuclear cells from patients with systemic lupus erythematosus
To explore whether the IFNL3/4 rs12979860 genotype may influence serum levels or production of interferon-inducible protein-10 (IP-10) by peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE).
Methods
Sixty-six patients with SLE and 22 healthy blood donors (controls) were included. The IFNL3/4 rs12979860 polymorphism was genotyped by real-time polymerase chain reaction. IP-10 levels in sera supernatants of IFNα stimulated peripheral blood mononuclear cells were measured by enzime-linked immunosorbent assay.
Results
Allelic frequencies were CC (29%), CT (52%) and TT (20%) in SLE, and CC (32%), CT (41%) and TT (27%) in healthy controls. Median serum IP-10 levels were higher in SLE patients than in controls (190.8 versus 118.1 pg/ml; p < 0.001), particularly in those with high disease activity (278.5 versus 177.2 pg/ml; p = 0.037). However, serum IP-10 levels were not influenced by IFNL3/4 genotypes. Higher IP-10 production by peripheral blood mononuclear cells was found in both SLE patients (median 519.3 versus 207.6 pg/ml; p = 0.012) and controls (median 454.0 versus 201.7 pg/ml; p = 0.034) carrying the IFNL3/4 C allele compared with carriers of the T allele.
Conclusions
Although IFNL3/4 rs12979860 allele C does not appear to influence serum IP-10 levels in SLE, it plays an important role in the production of IP-10 by peripheral blood mononuclear cells after IFNα stimulation.
MohanCPuttermanC. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol2015; 11: 329–341.
2.
TsokosGC. Systemic lupus erythematosus. N Engl J Med2011; 365: 2110–2121.
3.
HagbergNRonnblomL. Systemic lupus erythematosus – a disease with a dysregulated type I interferon system. Scand J Immunol2015; 82: 199–207.
4.
BaechlerECBatliwallaFMKarypisG, et al.Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A2003; 100: 2610–2615.
5.
BennettLPaluckaAKArceE, et al.Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med2003; 197: 711–723.
6.
FurieRKhamashtaMMerrillJT, et al.Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol2017; 69: 376–386.
7.
YaoYHiggsBWRichmanLWhiteBJallalB. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNalpha antibody, in systemic lupus erythematosus. Arthritis Res Ther2010; 12(Suppl.1): S6–S6.
8.
BoisvertMShoukryNH. Type III interferons in hepatitis C virus infection. Front Immunol2016; 7: 628–628.
9.
GeDFellayJThompsonAJ, et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature2009; 461: 399–401.
10.
ChenJYWangCMChenTD, et al.Interferon-lambda3/4 genetic variants and interferon-lambda3 serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese. Arthritis Res Ther2018; 20: 193–193.
11.
KotenkoSVGallagherGBaurinVV, et al.IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol2003; 4: 69–77.
12.
Prokunina-OlssonLMuchmoreBTangW, et al.A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet2013; 45: 164–171.
13.
SheppardPKindsvogelWXuW, et al.IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol2003; 4: 63–68.
14.
Amezcua-GuerraLMFerrusquia-TorizDCastillo-MartinezDMarquez-VelascoRChavez-RuedaAKBojalilR. Limited effectiveness for the therapeutic blockade of interferon alpha in systemic lupus erythematosus: A possible role for type III interferons. Rheumatology (Oxford)2015; 54: 203–205.
15.
BauerJWPetriMBatliwallaFM, et al.Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation study. Arthritis Rheum2009; 60: 3098–3107.
16.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
Sixtos-AlonsoMSAvalos-MartinezRSandoval-SalasR, et al.A genetic variant in the interleukin 28B gene as a major predictor for sustained virologic response in chronic hepatitis C virus infection. Arch Med Res2015; 46: 448–453.
19.
AbeHHayesCNOchiH, et al.Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol2011; 83: 1597–1607.
20.
BordiLCagliotiCGarbugliaAR, et al.IFNL4 and IFNL3 associated polymorphisms strongly influence the spontaneous IFN-alpha receptor-1 expression in HCV-infected patients. PLoS One2015; 10: e0117397–e0117397.
21.
LalleEBordiLCagliotiC, et al.IFN-alpha receptor-1 upregulation in PBMC from HCV naive patients carrying CC genotype. Possible role of IFN-lambda. PLoS One2014; 9: e93434–e93434.
22.
ZhangCXCaiLShaoK, et al.Serum IP-10 is useful for identifying renal and overall disease activity in pediatric systemic lupus erythematosus. Pediatr Nephrol2018; 33: 837–845.
23.
DarlingJMAerssensJFanningG, et al.Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology2011; 53: 14–22.
24.
LaggingMAskariehGNegroF, et al.Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One2011; 6: e17232–e17232.
25.
LiaoXPirapakaranTLuoXM. Chemokines and chemokine receptors in the development of lupus nephritis. Mediators Inflamm2016; 2016: 6012715–6012715.
26.
PadovanESpagnoliGCFerrantiniMHebererM. IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol2002; 71: 669–676.
27.
LanghansBKupferBBraunschweigerI, et al.Interferon-lambda serum levels in hepatitis C. J Hepatol2011; 54: 859–865.
28.
WuQYangQLourencoESunHZhangY. Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: Its correlation with disease activity. Arthritis Res Ther2011; 13: R88–R88.
29.
Amezcua-GuerraLMMarquez-VelascoRChavez-RuedaAK, et al.Type III interferons in systemic lupus erythematosus: Association between interferon lambda3, disease activity, and anti-Ro/SSA antibodies. J Clin Rheumatol2017; 23: 368–375.
30.
ZahnSRehkamperCKummererBM, et al.Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNlambda) in cutaneous lupus erythematosus. J Invest Dermatol2011; 131: 133–140.
31.
EslamMHashemAMLeungR, et al.Interferon-lambda rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun2015; 6: 6422–6422.
32.
Garcia-ValladaresIAtisha-FregosoYRichaud-PatinY, et al.Diminished expression of complement regulatory proteins (CD55 and CD59) in lymphocytes from systemic lupus erythematosus patients with lymphopenia. Lupus2006; 15: 600–605.
33.
BashalF. Hematological disorders in patients with systemic lupus erythematosus. Open Rheumatol J2013; 7: 87–95.
34.
RonnblomL. Potential role of IFNalpha in adult lupus. Arthritis Res Ther2010; 12(Suppl. 1): S3–S3.
35.
ChangMLKuoCJHuangHCChuYYChiuCT. Association between leptin and complement in hepatitis C patients with viral clearance: Homeostasis of metabolism and immunity. PLoS One2016; 11: e0166712–e0166712.
36.
BauerJWBaechlerECPetriM, et al.Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med2006; 3: e491–e491.
